Phospholipase Cβ3 in mouse and human dorsal root ganglia and spinal cord is a possible target for treatment of neuropathic pain

Treatment of neuropathic pain is a major clinical problem. This study shows expression of phospholipase ss3 (PLCss3) in mouse and human DRG neurons, mainly in small ones and mostly with a nonpeptidergic phenotype. After spared nerve injury, the pain threshold was strongly reduced, and systemic treat...

Full description

Saved in:
Bibliographic Details
Published in:Proceedings of the National Academy of Sciences - PNAS 2008-12, Vol.105 (50), p.20004-20008
Main Authors: Shi, Tie-Jun Sten, Liu, Su-Xing Leslie, Hammarberg, Henrik, Watanabe, Masahiko, Xu, Zhi-Qing David, Hökfelt, Tomas
Format: Article
Language:English
Subjects:
Antiserum
Behavioral neuroscience
Biological Sciences
Humans
Hyperalgesia
Nervous system trauma
Neurons
Pain
Receptors
Spinal cord
Spinal ganglia
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Treatment of neuropathic pain is a major clinical problem. This study shows expression of phospholipase ss3 (PLCss3) in mouse and human DRG neurons, mainly in small ones and mostly with a nonpeptidergic phenotype. After spared nerve injury, the pain threshold was strongly reduced, and systemic treatment of such animals with the unselective PLC inhibitor U73122 caused a rapid and long-lasting (48-h) increase in pain threshold. Thus, inhibition of PLC may provide a way to treat neuropathic pain.
ISSN:0027-8424
1091-6490
DOI:10.1073/pnas.0810899105